The Zhitong Finance App learned that Chardan analyst Daniil Gataulin will$Ocugen (OCGN.US) $The target price was lowered from $4 to $3.50, maintaining a “neutral” rating after the company announced financial results for the first quarter and provided an updated plan.

The analyst pointed out that Ocugen is continuing to make progress in the COVID-19 vaccine Covaxin, and registration of the drug OCU400 to treat hereditary retinal degeneration is also in the process. According to reports, OCU400 is a modified gene therapy candidate for treating retinitis pigmentosa (RP) caused by nuclear receptor subfamily 2 group E member 3 (NR2E3) and rhododin (RHO) gene mutations.